Background: Renal cell carcinoma (RCC) represents 2%-3% of all cancers of the Western countries. Currently, sunitinib, a receptor tyrosine kinase inhibitor, particularly of PDGF and VEGF receptors, is the first-line therapy for metastatic RCC (mRCC), with significant improvement in clinical outcome. However, there is a lack of predictive biomarkers of sunitinib response. Recently, others and our group suggested that the receptor tyrosine kinase AXL may modify the response to sunitinib.
Introduction
Kidney cancer is the seventh most common cancer in men and tenth most common cancer in woman worldwide [1] . Renal cell carcinoma (RCC) is responsible for 90% of all kidney cancer, and approximately 80% of these are clear cell tumors, with the other 20% being less common RCC subtypes, like papillary and chromophobe tumors [2, 3] . In Brazil kidney cancer is the 15th cancer in incidence with approximately 3,700 new cases per year responsible for more than 2,000 deaths per year [4] . Most clear cell cancer is sporadic while hereditary autosomal dominant syndromes are described as responsible for approximately 2%-3% of all RCCs, being the Von Hippel Lindau (VHL) disease the most common form [5, 6] . VHL disease is caused by a germline mutation in the VHL gene that predisposes to clear cell RCC and other proliferative vascular tumors [7] . VHL gene plays an important role, not only in hereditary but also in sporadic clear cell cancer, since inactivation of VHL leads to elevated levels of the transcription factor hypoxia-inducible factor 1α (HIF-1α) and subsequent overexpression of vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF), which promote tumor angiogenesis. Bi-allelic VHL gene alterations can occur through VHL gene mutations, hypermethylation of VHL gene promoter and loss of heterozygosity, which characterizes more than 80% of sporadic cases [6] .
In this scenario, the receptor tyrosine kinase inhibitors (TKI), sunitinib, an anti-angiogenic agent, was tested in phase III trial, leading to a longer progressing free survival when compared to interferon (median: 11 vs. 5 mo, respectively, hazard ratio (HR) ¼ 0.42; 95% CI: 0.32-0.54; P o 0.001) and an improved overall survival (OS) (median 26.4 vs. 21.8 mo, HR ¼ 0.82, 95% CI: 0.673-1.001, P ¼ 0.051) [8, 9] . Consequently, sunitinib was approved and established as a standard of care in the treatment of advanced RCC worldwide [5, [10] [11] [12] . Despite of this rational, TKIs rarely cause durable tumor regressions and most patients will experience disease progression after an initial period of response [13] .
Remarkable efforts are being made to identify biomarkers that may predict response to select and treat more effectively patients with metastatic RCC (mRCC) [14] . AXL, a gene that encodes a receptor tyrosine kinase, is involved with a wide variety of cancerous hallmarks such as proliferation, survival, evasion from apoptosis, enhanced angiogenesis, and invasiveness [15, 16] . Recently, AXL have been suggested as a biomarker of poor prognosis and a potential target for different types of cancers [17, 18] , including RCC [19, 20] . Previously, our group suggested that in glioblastoma cell lines, AXL can constitute a predictive biomarker for sunitinib response [21, 22] . In this study, we evaluated the AXL presence in the primary tumor through its expression in a cohort of 64 patients with mRCC treated with sunitinib and its association with clinicalpathological features and clinical outcome.
Materials and methods

Patients and sampling
Sixty-four patients with mRCC treated with sunitinib between 2008 and 2014 at Barretos Cancer Hospital were included in this study. Patient inclusion criteria comprised a diagnosis of mRCC of any pathologic subtype that had received at least 1 course of sunitinib in any line and had enough tissue samples for immunohistochemistry analysis. We also divided the patients into 2 groups, the clear cell and non-CCC (NCCC), due to different responses to sunitinib [20] . Baseline data including those previously found to have prognostic value [23, 24] were collected retrospectively on all patients using uniform database templates to ensure consistent data collections and a SPSS databank was created. Laboratory values were standardized according to the local laboratory. The project was approved by local ethical committees (No. 837/2014).
Paraffin-embedded tumor samples from all 64 patients were retrieved from the Pathology Department of Barretos Cancer Hospital, Barretos, Brazil. All 64 samples were from the primary renal tumor (49 patients the material came from a previous nephrectomy, and 15 patients the material came from a biopsy from the primary tumor), and from these patients we were able to retrieve 41 normal adjacent renal tissue and 14 metastatic renal tissue. All tumor samples were collected before treatment with sunitinib. The tumor tissue were classified according to the latest criteria [25] , reviewed by experienced pathologists to select representative sections (tumor and normal) for TMA (tissue microarray) construction. The TMA blocks were done containing 2 representative areas of each primary cancer of RCC tissue, metastatic tissue, and when available the normal counterpart (1 mm diameter core).
Immunohistochemistry analysis
Representative 4-µm thick sections of TMA were subjected to immunohistochemistry according to the streptavidin-biotin peroxidase complex system. Briefly, FFPE RCC tissue section were deparaffinised in oven at 80°C for 1 hour, following by antigen retriever by PT-LINK-Dako, using commercial buffer Envision flex target retrieval solution high ph. x1, from Dako (pH ¼ 9). The sections were then incubated with anti-Axl antibody (dilution 1:50, Cat #AF154 R&D Systems, Minneapolis, MN) at room temperature for 2 hours. As positive control, we used normal breast tissue, which showed membranous AXL staining of luminal ductal cells with variable cytoplasmic staining, and cell-block of SNB-19 cell line, known in previous studies of our group for high AXL levels [21, 26] .
The score used was the sum of the percentage of cytoplasm positive cells (negative, 0%-o1% positive cells; 1, 1%-10% positive cells; 2, 410%-50% positive cells; 3, 4 50% positive cells) and the staining intensity (0, negative; 1, weak; 2, moderate and 3, strong). Samples with scores 0 to 2 were considered negative for AXL expression and those with score 3 to 6 were considered positive for AXL expression, as previously described for receptor tyrosine kinase immunohistochemistry analysis [27] [28] [29] .
Statistical analyses
Cumulative survival probabilities were calculated using the Kaplan-Meier method. Differences between survivals were tested using the log-rank test. Our primary end point was OS due to the retrospective analyses, which hamper a proper progression-free survival. OS was defined as the time from metastatic diagnoses to death as a result of any cause or was censored at the date of last follow-up. Association between OS and prognostic factors were assessed by using the long-rank test in univariable analysis. Correlations between AXL expression and available clinic-pathological data were performed using the Pearson's chi-square test (χ 2 test) or Fisher's exact test. The Cox proportional hazard model was undertaken subsequently in multivariable analyses by using a step-wise procedure with a significance level of 0.2 for entering and removing variables.
The level of significance in the statistical analysis were indicated as P o 0.05. The statistical analysis was performed using SPSS software for Windows, version 21.0.
Results
Patient clinical-pathological features
Overall, 64 patients were included in this analysis that were divided in 2 major subgroups: 51 (79.6%) CCC cases; and 13 (20.4%) NCCC cases (Table 1) . Among the CCC subgroup, 4 (6.3%) cases were CCC with sarcomatoid features, and within the NCCC group, 9 cases (14%) were papillary RCC and 4 (6.3%) were RCC, unclassified, where 2 cases had pure sarcomatoid features. Forty-two (65.6%) were male and 22 (34.4%) were female with a median age of 57-years old (range: 30-81). The clinical parameters available for the two groups showed similar profile ( Table 1 ). The median OS for the entire cohort of 64 patients was 25.6 months (95% CI: 11.6-39.7 mo, Fig. 1A ). The mean follow up was 18.5 months. The CCC cohort, which compromised 51 patients, the OS was 26.3 months (95% CI: 6.0-46.5 mo) and the NCCC cohort, which compromised 13 patients, the OS was 10.3 months (95% CI: 5.1-15 mo, Fig. 1B) .
In the first line therapy 46 (72%) patients received a TKI, and sunitinib was the drug of choice in the 45 patients, followed by 16 (25%) patients that received interferon alfa. One patient received chemotherapy as first line and one patient was not treated with any systemic therapy. Of the 45 patients that received sunitinib as first line, 26 (58%) had progressed while using sunitinib, 11 (24%) had partial response or stable disease, and 8 (18%) the data were missing.
Seventeen patients did not receive sunitinib as first line, but it was giving at point of treatment. Thirteen patients received in the second line, three patients received in the third line and one patient in the fourth line. Of those patients 8 (47%) had progressed disease and 9 (53%) had partial response or stable disease while in use of sunitinib.
AXL expression in patients with RCC
The immunohistochemistry analysis of the 64 cases showed a wide variety of expression patterns, from negative to highly positive membranous or cytoplasmatic immunostaining (Fig. 2) . Negative immunostaining (scores 0-2þ) ( Fig. 2A) was present in 34 (53.2%) patients and positive immunostaining (scores: 3þ to 6þ) ( Fig. 2B and C) was present in 30 (46.8%) of 64 cases. Endothelial cells were highly positive and it was used as internal control (Fig. 2) . When analyzed all AXL scores cases separately from 0 through 6þ, it was seen that 26 (41%) cases had score 0, 8 (13%) had score 2þ, 4 (6%) had score 3þ, 15 (23%) had score 4þ, 4(6%) had score 5þ and 7 (11%) had score 6þ (Fig. 3) .
We also evaluated the AXL positivity in the normal renal tissue of 41 patients and in the metastasis tissue of 14 patients. We could observe a rising in AXL positivity from normal renal tissue to tumor renal tissue and from a tumor renal tissue to a metastatic renal tissue, but with no statistical significance (Fig. 4A and B) . There was no statistical difference (P ¼ 0.235) among the distinct histological subtypes. The clear cell subtype depicted a 43.1% (22/51) of AXL positivity, whereas the nonclear cell subtype showed a 61.5% (8/13) of positive AXL expression.
Association between AXL expression and clinicalpathological features
The univariate analysis between the AXL expression and clinical-pathological features for both histological subtypes combined, demonstrated that AXL positivity was associated with poor prognostic feature, like thrombocytosis, time from diagnostic to treatment less than a year, presence of bone metastasis, presence of brain metastasis and sarcomatoid histology, but none were statically significant besides progression while in sunitinib therapy (Table 2) . In multivariate analysis, none of the variables had statically significance correlation with AXL positivity.
When analyze only the patients with CCC, in univariate analysis we also demonstrated that AXL positivity was associated with poor prognostic features, like thrombocytosis, time from diagnoses to treatment less than a year, presence of bone metastasis, presence of brain metastasis and sarcomatoid histology, but only older patients and progression while in sunitinib therapy was statistical significant (Table 2 ). In multivariate analysis older patients (HR ¼ 4.75; 95% CI: 1.2-17.7; P ¼ 0.020) and presence of bone metastasis (HR ¼ 4.78; 95% CI: 1.17-19.4; P ¼ 0.029) were significantly associated with AXL positivity.
The overall response while using sunitinib of the entire cohort of 64 patients, 35 (54.7%) patients had progression, 19 (29.7%) had stable or response disease, and 10 (15.6%) patients we were not able to access a response rate. In the univariate analysis, between all patients that used sunitinib and had AXL positivity, 21 (77.8%) patients had disease progression and 6 (22.2%) patients had response or stable disease, whereas between patients with AXL negativity, 14 (51.9%) patients had disease progression and 13 (48.1%) patients had response or stable disease (P ¼ 0.046) (Fig. 5A) . Among only those with clear cell subtype, patients with AXL positivity, 16 (80%) patients had disease progression and 4 (20%) patients had response or stable disease while using sunitinib, while between patients with AXL negativity, 10 (43.5%) patients had disease progression and 13 (56.5%) patients had response or stable disease (P ¼ 0.027) (Fig. 5B) .
AXL expression predicts poor prognosis in patients with RCC
We further evaluated the association of AXL expression with patient outcome. We found that patients with positive AXL expression had a median OS of 41.2 months (95% CI: 10.1-72 mo), compared to 19 months (95% CI: 7.0-32 mo) of patients AXL negative, however, not reaching statistical significance (P ¼ 0.14) (Fig. 6A) . The multivariate analysis showed that AXL expression was a poor prognostic factor in patients with mRCC (HR ¼ 2.007; CI: 1.006-4.006; P ¼ 0.048). In addition of the positivity for AXL, other prognostic factors were absence of nephrectomy, more than 1 site of metastasis and bone metastasis (Table 3) . Interestingly, when we stratified the positive AXL expression (3þ thought 6þ) there were no difference in OS between groups (data not shown).
When we stratified by histological subtype, the CCC AXL negative cases (n ¼ 22), exhibited an OS of 43.3 months (95% CI: 18.1-68 mo), whereas in the AXL positive cases (n ¼ 29) was of 13.4 months (95% CI: 4.0-22 mo), also not reaching a significance (P ¼ 0.055) (Fig. 6B) . In multivariate analysis, AXL positivity in CCC was associated with poor prognostic along with absence of nephrectomy, Karnofsky performance status less than 70, more than 1 site of metastasis and presence of liver metastasis (Table 4) .
Discussion
Despite the advanced systemic treatment in mRCC in the past 10 years and the multiples drugs available [5, 12] , treatment decision is based in medical expertise rather than in objective predictive biomarkers [30] . With the in vitro evidences that tyrosine kinase AXL expression can be a predictive biomarker to sunitinib [21] , our group investigated in the present study whether AXL overexpression in tumor renal tissue is associated with response rate in mRCC patients treated with sunitinib.
We analyzed 64 patients with mRCC treated with sunitinib. Demographic parameters and OS were similar with previous studies [23, 31] . We could not correlate increased expression AXL with tumor response to sunitinib. However, we observed that AXL positivity in kidney cancer tissue is associated with shorter survival and a lack of response to the treatment.
AXL overexpression in tumor tissue has been associated with poor prognoses in a variety of cancers, probably because its involvement in various aspects of cellular signaling and it is implication in a wide variety of hallmarks of cancer [16] . Recent reports showed that high tumor AXL was an independent prognostic factor in patients with RCC [32, 33] . Gustafsson et al. [32] in 2009, reported the tumor Axl mRNA was as an independent prognostic factor in cancer-specific survival, and Rankin et al. [33] in 2015 analyzed AXL expression in human RCC tissue within The Cancer Genome Atlas (TCGA) and samples with strong AXL expression was associated patients with reduced survival compared with patients whose samples had weak AXL expression. Our report, represents the first association of AXL positivity by immunohistochemistry with reduced survival in patients with mRCC treated with sunitinib. AXL has been suggested to promote both intrinsic and acquired resistance to different treatments, from chemotherapy to molecular targets [15] . In RCC xenograft models upregulation of AXL and MET showed resistance to longterm sunitinib therapy, as well as resensitisation to sunitinib after AXL and MET inhibition via treatment with the TKI cabozantinib [34] . Cabozantinib has been demonstrated efficacy in 2 trials in mRCC [35, 36] . A large phase III trial demonstrated that cabozantinib increased OS, delayed disease progression, and improved the objective response compared with everolimus after failing one or more anti-VEGF [35] . Recently cabozantinib was compared to sunitinib in first-line therapy in intermediated and poor risk IMDC (International Metastatic Renal Cell Carcinoma Database Consortium) group patients and was observed that cabozantinib had benefit in progression-free survival and overall response rate over sunitinib [36] . None of these 2 trials used a biomarker for predictive response to therapy. Despite of a variety promising new drugs emerging in the scenario of first-line therapy of mRCC, sunitinib might still have its place in some patients, namely in those cases with lack of AXL expression.
Our sample is representative of mRCC treated with sunitinib. However, the results from CCC setting have limited inference due to small exploratory sample (n ¼ 51). Additionally, the significance of survival differences in CCC according to AXL staining is tangential. Unfortunately, we were unable to define risk criteria according Motzer et al. [24] and Heng et al. [23] for all patients due to paucity of clinical data. Therefore, further studies are warranted to extend and validate the present findings.
Conclusion
In the present study we reported that AXL was a prognostic biomarker in patients with mRCC treated with sunitinib. Interesting, AXL constitute also a target of the new drug cabozantinib, which demonstrated efficacy in the treatment in mRCC patients. Further studies are needed to demonstrate that cabozantinib is a target against patients with increased AXL expression.
